Cigna Corp (CI)
300.87
+0.00 (0.00%)
NYSE · Last Trade: Sep 2nd, 4:15 AM EDT
Abbott Laboratories currently trades at $131.61 per share and has shown little upside over the past six months, posting a small loss of 4.6%. The stock also fell short of the S&P 500’s 8.8% gain during that period.
Via StockStory · August 28, 2025
The current financial market is witnessing a stark divergence in sector performance, painting a complex picture for investors and the broader economy. While the technology sector, particularly its AI-driven segments, continues its meteoric rise, alongside robust showings from Utilities and Financials, other traditionally stable sectors like Healthcare, Energy, and Industrials
Via MarketMinute · August 27, 2025
A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments.
Via Benzinga · August 26, 2025
Cigna Stock Slides 8% On Thursday But Wells Fargo Analyst Is Surprised: Here’s What Happenedstocktwits.com
Via Stocktwits · July 31, 2025
Via Benzinga · August 21, 2025
Via Benzinga · August 18, 2025
Looking back on health insurance providers stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Cigna (NYSE:CI) and its peers.
Via StockStory · August 14, 2025
Via Benzinga · August 14, 2025
A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp.
Via Benzinga · July 31, 2025
This top health insurer scans as a downright bargain at current levels.
Via The Motley Fool · August 14, 2025
Speculation over a potential Berkshire Hathaway stake, alongside big moves from notable institutional investors, has added to the momentum in UnitedHealth shares.
Via Stocktwits · August 14, 2025
Health insurance company Cigna (NYSE:CI) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.1% year on year to $67.18 billion. Its non-GAAP profit of $7.20 per share was 0.6% above analysts’ consensus estimates.
Via StockStory · August 13, 2025
Cigna’s second quarter results were met with a significant negative market reaction, reflecting investor concerns despite revenue and adjusted earnings per share both coming in ahead of Wall Street expectations. Management attributed the quarter’s results to continued momentum in its Evernorth services platform and the resilience of its U.S. employer business. However, persistent elevated medical costs, especially in the commercial and individual exchange segments, remained a notable challenge. CEO David Cordani described the company’s performance as “differentiated,” but acknowledged industry disruption and the necessity of ongoing portfolio adjustments. Management also highlighted product innovation, such as new GLP-1 benefit options and AI-powered virtual assistance, as key contributors to maintaining customer engagement and operational execution.
Via StockStory · August 13, 2025
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
Via StockStory · August 8, 2025
Via Benzinga · August 1, 2025
Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
Via Benzinga · August 1, 2025
According to a Bloomberg News report, Trump already met JPMorgan Chase & Co. CEO Jamie Dimon last week at the White House, followed by talks with Goldman Sachs CEO David Solomon on Thursday.
Via Stocktwits · July 31, 2025
Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · July 31, 2025
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Thursday and stay ahead of the market trends.
Via Chartmill · July 31, 2025
Health insurance company Cigna (NYSE:CI) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 11.1% year on year to $67.18 billion. Its non-GAAP profit of $7.20 per share was 0.6% above analysts’ consensus estimates.
Via StockStory · July 31, 2025
Cigna Group (NYSE:CI) beat Q2 revenue estimates but slightly missed on EPS, reaffirming full-year guidance. Shares rose 4.4% pre-market as investors focused on growth.
Via Chartmill · July 31, 2025